June, 2024- BD and Edwards Lifesciences’ announced a definitive agreement under which BD will acquire Edwards’ Critical Care product group (“Critical Care”), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD’s portfolio of smart connected care solutions.
Critical Care is a high-growth, innovative industry leader in advanced patient monitoring with advanced AI algorithms serving millions of patients globally. Critical Care invented the hemodynamic monitoring category, and its solutions are currently used in more than 10,000 hospitals globally to better understand the cardiovascular condition in real-time for critically ill patients, which helps improve outcomes. Hemodynamic monitoring and medication management technologies are often used simultaneously in the operating room or intensive care units, creating longer-term opportunities for meaningful innovation and interoperability across the care continuum. Critical Care has approximately 4,500 employees with most based in Irvine, California. In 2023, the business generated more than $900 million in revenue.
Also Read: BD and Techcyte Collaborate for AI-Based Cervical Cytology System in Pap Testing
“Critical Care expands BD’s portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement BD’s existing technologies serving operating rooms and intensive care units,” said Tom Polen, chairman, chief executive officer and president of BD.
Critical Care’s portfolio includes the gold-standard Swan Ganz pulmonary artery catheter, minimally invasive sensors, non-invasive cuffs, tissue oximetry sensors and monitors. Advanced data analytics with machine learning and AI-based predictive and prescriptive algorithms drive its smart technologies, helping clinicians better understand current and future patient conditions and providing clinical decision support tools.
